For Pfizer, Vaccines and Vyndaqel In The Q1 Spotlight
Executive Summary
Earnings preview: Pfizer's newly launched rare disease drug Vyndaqel and vaccines could be impacted by COVID-19. Investors will also be eager to hear more about the timeline for closing the Upjohn transaction.